Concise Review: Sowing the seeds of a fruitful harvest: Hematopoietic stem cell mobilization

Stem Cells

Volumn 31, Issue 12, 2013, Pages 2599-2606

  Hoggatt, Jonathan ^a   Speth, Jennifer M ^b   Pelus, Louis M ^b  

^a HARVARD UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AMD3100 (plerixafor); CXCR4; Granulocyte colony stimulating factor; Hematopoietic stem cell; Mobilization; Stem cell niche

Indexed keywords

5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; ANTINEOPLASTIC AGENT; BETAFECTIN; BIO 5192; CANNABINOID DERIVATIVE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; COLOMINIC ACID; CTCE 0021; CTCE 0214; CYCLOPHOSPHAMIDE; DEFIBROTIDE; DNA; DOXORUBICIN; FUCOIDIN; GELATINASE B; GLYCOSAMINOGLYCAN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDOMIMETIC AGENT; PLERIXAFOR; PROPRANOLOL; PROSTAGLANDIN E2; PROTEIN INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA; T 140; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APHERESIS; ARTICLE; BLOOD; BONE MARROW; BONE PAIN; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CELL DIVISION; CELL HOMING; CELL LINE; CHIMERA; CLINICAL TRIAL (TOPIC); COLONY FORMING UNIT; CRYOPRESERVATION; DNA REPLICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENGRAFTMENT; FATIGUE; FOOD AND DRUG ADMINISTRATION; GRANULOCYTE; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEOSTASIS; HOSPITALIZATION; HUMAN; LEUKOCYTE; LEUKOCYTE TRANSFUSION; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROTEIN FUNCTION; RODENT; SPLEEN; STEM CELL MOBILIZATION; ANIMAL; PROCEDURES; STEM CELL NICHE;

ANIMALS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; STEM CELL NICHE;

EID: 84890542983     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1574     Document Type: Article

References (152)

1. Bell AJ, Figes A, Oscier DG et al. Peripheral blood stem cell autografts in the treatment of lymphoid malignancies: Initial experience in three patients. Br J Haematol 1987;66:63-68.
2. To LB, Dyson PG, Branford AL et al. Peripheral blood stem cells collected in very early remission produce rapid and sustained autologous haemopoietic reconstitution in acute nonlymphoblastic leukaemia. Bone Marrow Transplant 1987;2:103-108.
3. Reiffers J, Bernard P, David B et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 1986;14:312-315.
4. Kessinger A, Armitage JO, Landmark JD et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986;14:192-196.
5. Korbling M, Dorken B, Ho AD et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986;67:529-532.
6. Lorenz E, Uphoff D, REID TR et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951;12:197-201.
7. Jacobson LO, Simmons EL, Marks EK et al. Recovery from radiation injury. Science 1951;113:510-511.
8. Jacobson LO, Simmons EL, Marks EK et al. The role of the spleen in radiation injury and recovery. J Lab Clin Med 1950;35:746-770.
9. Main JM, Prehn RT. Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst 1955;15:1023-1029.
10. Ford CE, Hamerton JL, Barnes DW et al. Cytological identification of radiation-chimaeras. Nature 1956;177:452-454.
11. Makinodan T. Circulating rat cells in lethally irradiated mice protected with rat bone marrow. Proc Soc Exp Biol Med 1956;92:174-179.
12. Nowell PC, Cole LJ, Habermeyer JG et al. Growth and continued function of rat marrow cells in x-radiated mice. Cancer Res 1956; 16:258-261.
13. Trentin JJ. Mortality and skin transplantability in x-irradiated mice receiving isologous, homologous or heterologous bone marrow. Proc Soc Exp Biol Med 1956;92:688-693.
14. Vos O, Davids JA, Weyzen WW et al. Evidence for the cellular hypothesis in radiation protection by bone marrow cells. Acta Physiol Pharmacol Neerl 1956;4:482-486.
15. Wu AM, Till JE, Siminovitch L et al. A cytological study of the capacity for differentiation of normal hemopoietic colony-forming cells. J Cell Physiol 1967;69:177-184.
16. Wu AM, Till JE, Siminovitch L et al. Cytological evidence for a relationship between normal hemotopoietic colony-forming cells and cells of the lymphoid system. J Exp Med 1968;127:455-464.
17. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 1961;14: 213-222.
18. Siminovitch L, McCulloch EA, Till JE. The distribution of colonyforming cells among spleen colonies. J Cell Physiol 1963;62:327-336.
19. Leung CG, Xu Y, Mularski B et al. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J Exp Med 2007;204:1603-1611.
20. Becker AJ, McCulloch EA, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963;197:452-454.
21. Woenckhaus E. Beitrag zur Allgemeinwirkung der Roentgenstrahlen. Arch F Exp Path Und Pharm 1930;150:182.
22. Brecher G, Cronkite EP. Post-radiation parabiosis and survival in rats. Proc Soc Exp Biol Med 1951;77:292-294.
23. Bond VP, Fliedner TM, Cronkite EP et al. Proliferative potentials of bone marrow and blood cells studied by in vitro uptake of H3-thymidine. Acta Haematol 1959;21:1-15.
24. Bond VP, Cronkite EP, Fliedner TM et al. Deoxyribonucleic acid synthesizing cells in peripheral blood of normal human beings. Science 1958;128:202-203.
25. Popp RA. Erythrocyte repopulation in X-irradiated recipients of nucleated, peripheral blood cells of normal mice. Proc Soc Exp Biol Med 1960;104:722-724.
26. Goodman JW, Hodgson GS. Evidence for stem cells in the peripheral blood of mice. Blood 1962;19:702-714.
27. Lewis JP, Passovoy M, Freeman M et al. The repopulating potential and differentiation capacity of hematopoietic stem cells from the blood and bone marrow of normal mice. J Cell Physiol 1968;71: 121-132.
28. Fliedner TM, Flad HD, Bruch C et al. Treatment of aplastic anemia by blood stem cell transfusion: A canine model. Haematologica 1976;61:141-156.
29. Storb R, Epstein RB, Ragde H et al. Marrow engraftment by allogeneic leukocytes in lethally irradiated dogs. Blood 1967;30:805-811.
30. Cavins JA, Scheer SC, Thomas ED et al. The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at 280 -C. Blood 1964;23:38-42.
31. Buckner D, Graw RG, Jr., Eisel RJ et al. Leukapheresis by continuous flow centrifugation (CFC) in patients with chronic myelocytic leukemia (CML). Blood 1969;33:353-369.
32. Buckner D, Eisel R, Perry S. Blood cell separation in the dog by continuous flow centrifugation. Blood 1968;31:653-672.
33. Freireich EJ, Judson G, Levin RH. Separation and collection of leukocytes. Cancer Res 1965;25:1516-1520.
34. Chervenick PA, Boggs DR. In vitro growth of granulocytic and mononuclear cell colonies from blood of normal individuals. Blood 1971;37:131-135.
35. Kurnick JE, Robison WA. Colony growth of human peripheral white blood cells in vitro. Blood 1971;37:136-141.
36. McCredie KB, Hersh EM, Freireich EJ. Cells capable of colony formation in the peripheral blood of man. Science 1971;171:293-294.
37. Abrams RA, Glaubiger D, Appelbaum FR et al. Result of attempted hematopoietic reconstitution using isologous, peripheral blood mononuclear cells: A case report. Blood 1980;56:516-520.
38. Hershko C, Gale RP, Ho WG et al. Cure of aplastic anaemia in paroxysmal nocturnal haemoglobinuria by marrow transfusion from identical twin: Failure of peripheral-leucocyte transfusion to correct marrow aplasia. Lancet 1979;1:945-947.
39. Fliedner TM, Korbling M, Calvo W et al. Cryopreservation of blood mononuclear leukocytes and stem cells suspended in a large fluid volume. A preclinical model for a blood stem cell bank. Blut 1977; 35:195-202.
40. Goldman JM, Johnson SA, Catovsky D et al. Autografting for chronic granulocytic leukemia. N Engl J Med 1981;305:700.
41. Korbling M, Burke P, Braine H et al. Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol 1981;9:684-690.
42. Goldman JM. Autografting cryopreserved buffy coat cells for chronic granulocytic leukaemia in transformation. Exp Hematol 1979;7(suppl 5):389-397.
43. Greenberg P, Bax I, Mara B et al. Alterations of granulopoiesis following chemotherapy. Blood 1974;44:375-383.
44. Bull JM, DeVita VT, Carbone PP. In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas. Blood 1975;45:833-842.
45. Senn JS, McCulloch EA. Kinetics of regeneration after cyclophosphamide in human marrow assessed by a cell culture method. Exp Hematol 1970;20:8-9.
46. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031-1039.
47. Stiff PJ, Murgo AJ, Wittes RE et al. Quantification of the peripheral blood colony forming unit-culture rise following chemotherapy. Could leukocytaphereses replace bone marrow for autologous transplantation? Transfusion 1983;23:500-503.
48. To LB, Shepperd KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990;18: 442-447.
49. To LB, Haylock DN, Kimber RJ et al. High levels of circulating haemopoietic stem cells in very early remission from acute nonlymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 1984;58:399-410.
50. Welte K, Platzer E, Lu L et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985;82:1526-1530.
51. Platzer E, Oez S, Welte K et al. Human pluripotent hemopoietic colony stimulating factor: Activities on human and murine cells. Immunobiology 1986;172:185-193.
52. Nagata S, Tsuchiya M, Asano S et al. The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor. EMBO J 1986;5:575-581.
53. Souza LM, Boone TC, Gabrilove J et al. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 1986;232:61-65.
54. Welte K, Bonilla MA, Gillio AP et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987;165:941-948.
55. Duhrsen U, Villeval JL, Boyd J et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-2081.
56. Ikebuchi K, Ihle JN, Hirai Y et al. Synergistic factors for stem cell proliferation: Further studies of the target stem cells and the mechanism of stimulation by interleukin-1, interleukin-6, and granulocyte colony-stimulating factor. Blood 1988;72:2007-2014.
57. Metcalf D, Nicola NA. Proliferative effects of purified granulocyte colony-stimulating factor (G-CSF) on normal mouse hemopoietic cells. J Cell Physiol 1983;116:198-206.
58. Ikebuchi K, Clark SC, Ihle JN et al. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 1988;85: 3445-3449.
59. Gabrilove JL, Jakubowski A, Fain K et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988;82:1454-1461.
60. Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-1422.
61. Bronchud MH, Scarffe JH, Thatcher N et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809-813.
62. Morstyn G, Campbell L, Souza LM et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988;1:667-672.
63. Tamura M, Hattori K, Nomura H et al. Induction of neutrophilic granulocytosis in mice by administration of purified human native granulocyte colony-stimulating factor (G-CSF). Biochem Biophys Res Commun 1987;142:454-460.
64. Kennedy MJ, Davis J, Passos-Coelho J et al. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4- hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer. Cancer Res 1993;53:5424-5428.
65. McQuaker IG, Hunter AE, Pacey S et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit. J Clin Oncol 1997;15:451-457.
66. Jansen J, Thompson EM, Hanks S et al. Hematopoietic growth factor after autologous peripheral blood transplantation: Comparison of G-CSF and GM-CSF. Bone Marrow Transplant 1999;23:1251-1256.
67. Nemunaitis J, Rosenfeld CS, Ash R et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:949-954.
68. Stem Cell Trialists' Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-Analysis of nine randomized trials. J Clin Oncol 2005;23:5074-5087.
69. Anderlini P, Rizzo JD, Nugent ML et al. Peripheral blood stem cell donation: An analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001;27:689-692.
70. Anderlini P, Przepiorka D, Korbling M et al. Blood stem cell procurement: Donor safety issues. Bone Marrow Transplant 1998; 21(suppl 3):S35-S39.
71. Rowley SD, Donaldson G, Lilleby K et al. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001;97:2541-2548.
72. Fortanier C, Kuentz M, Sutton L et al. Healthy sibling donor anxiety and pain during bone marrow or peripheral blood stem cell harvesting for allogeneic transplantation: Results of a randomised study. Bone Marrow Transplant 2002;29:145-149.
73. Platzbecker U, Prange-Krex G, Bornhauser M et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001;41:184-189.
74. Stroncek D, Shawker T, Follmann D et al. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003;43:609-613.
75. Falzetti F, Aversa F, Minelli O et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999;353:555.
76. Becker PS, Wagle M, Matous S et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997;3:45-49.
77. Balaguer H, Galmes A, Ventayol G et al. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004;44:1260-1261.
78. Kroger N, Renges H, Sonnenberg S et al. Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 2002;29:727-730.
79. Hill JM, Syed MA, Arai AE et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 2005;46:1643-1648.
80. Lindemann A, Rumberger B. Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF). Eur J Cancer 1993;29A:2338-2339.
81. Pusic I, Jiang SY, Landua S et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14: 1045-1056.
82. Pavone V, Gaudio F, Console G et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37:719-724.
83. Hosing C, Saliba RM, Ahlawat S et al. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009;84:335-337.
84. Gordan LN, Sugrue MW, Lynch JW et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003;44:815-820.
85. Akhtar S, Weshi AE, Rahal M et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: A single institution result of 168 patients. Leuk Lymphoma 2008;49: 769-778.
86. Boeve S, Strupeck J, Creech S et al. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: Risk factors, cytokine use and cost. Bone Marrow Transplant 2004;33:997-1003.
87. Sugrue MW, Williams K, Pollock BH et al. Characterization and outcome of "hard to mobilize"' lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000;39:509-519.
88. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995;86:3961-3969.
89. Gertz MA, Wolf RC, Micallef IN et al. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010;45: 1396-1403.
90. Hosing C, Smith V, Rhodes B et al. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion 2011;51:1300-1313.
91. Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002;3:687-694.
92. Broxmeyer HE, Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005;201:1307-1318.
93. Broxmeyer HE, Hangoc G, Cooper S et al. AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis. Ann N Y Acad Sci 2007;1106:1-19.
94. Devine SM, Vij R, Rettig M et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112:990-998.
95. Liles WC, Broxmeyer HE, Rodger E et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-2730.
96. Liles WC, Rodger E, Broxmeyer HE et al. Augmented mobilization and collection of CD341 hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005;45:295-300.
97. Pelus LM, Bian H, Fukuda S et al. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Exp Hematol 2005;33: 295-307.
98. Abraham M, Biyder K, Begin M et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 2007;25:2158-2166.
99. Iyer CV, Evans RJ, Lou Q et al. Rapid and recurrent neutrophil mobilization regulated by T134, a CXCR4 peptide antagonist. Exp Hematol 2008;36:1098-1109.
100. Shen H, Cheng T, Olszak I et al. CXCR-4 desensitization is associated with tissue localization of hemopoietic progenitor cells. J Immunol 2001;166:5027-5033.
101. Zhong R, Law P, Wong D et al. Small peptide analogs to stromal derived factor-1 enhance chemotactic migration of human and mouse hematopoietic cells. Exp Hematol 2004;32:470-475.
102. Cramer DE, Wagner S, Li B et al. Mobilization of hematopoietic progenitor cells by yeast-derived beta-glucan requires activation of matrix metalloproteinase-9. Stem Cells 2008;26:1231-1240.
103. Patchen ML, Liang J, Vaudrain T et al. Mobilization of peripheral blood progenitor cells by Betafectin PGG-Glucan alone and in combination with granulocyte colony-stimulating factor. Stem Cells 1998; 16:208-217.
104. Frenette PS, Weiss L. Sulfated glycans induce rapid hematopoietic progenitor cell mobilization: Evidence for selectin-dependent and independent mechanisms. Blood 2000;96:2460-2468.
105. Sweeney EA, Priestley GV, Nakamoto B et al. Mobilization of stem/ progenitor cells by sulfated polysaccharides does not require selectin presence. Proc Natl Acad Sci USA 2000;97:6544-6549.
106. Sweeney EA, Lortat-Jacob H, Priestley GV et al. Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: Involvement in mobilization of stem/progenitor cells. Blood 2002;99: 44-51.
107. Kubonishi S, Kikuchi T, Yamaguchi S et al. Rapid hematopoietic progenitor mobilization by sulfated colominic acid. Biochem Biophys Res Commun 2007;355:970-975.
108. Albanese P, Caruelle D, Frescaline G et al. Glycosaminoglycan mimetics-induced mobilization of hematopoietic progenitors and stem cells into mouse peripheral blood: Structure/function insights. Exp Hematol 2009;37:1072-1083.
109. Craddock CF, Nakamoto B, Andrews RG et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokineinduced mobilization in primates and mice. Blood 1997;90:4779-4788.
110. Papayannopoulou T, Priestley GV, Nakamoto B et al. Molecular pathways in bone marrow homing: Dominant role of alpha(4)beta(1) over beta(2)-integrins and selectins. Blood 2001;98:2403-2411.
111. Kikuta T, Shimazaki C, Ashihara E et al. Mobilization of hematopoietic primitive and committed progenitor cells into blood in mice by anti-vascular adhesion molecule-1 antibody alone or in combination with granulocyte colony-stimulating factor. Exp Hematol 2000;28: 311-317.
112. Papayannopoulou T, Priestley GV, Nakamoto B. Anti-VLA4/VCAM- 1-induced mobilization requires cooperative signaling through the kit/ mkit ligand pathway. Blood 1998;91:2231-2239.
113. Ramirez P, Rettig MP, Uy GL et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009;114:1340-1343.
114. Ting M, Day B, Spanevello M et al. Activation of ephrin A proteins influences hematopoietic stem cell adhesion and trafficking patterns. Exp Hematol 2010;38:1087-1098.
115. Carlo-Stella C, Di NM, Magni M et al. Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice. Cancer Res 2002;62:6152-6157.
116. Scalia R, Kochilas L, Campbell B et al. Effects of defibrotide on leukocyte-endothelial cell interaction in the rat mesenteric vascular bed: Role of P-selectin. Methods Find Exp Clin Pharmacol 1996;18: 669-676.
117. Pellegatta F, Lu Y, Radaelli A et al. Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion. BR. J Pharmacol 1996;118: 471-476.
118. Fibbe WE, Pruijt JF, van KY et al. The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem-cell mobilization. Semin Hematol 2000;37(1 suppl 2):19-24.
119. Pelus LM, Horowitz D, Cooper SC et al. Peripheral blood stem cell mobilization. A role for CXC chemokines. Crit Rev Oncol Hematol 2002;43:257-275.
120. Fukuda S, Bian H, King AG et al. The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood 2007;110:860-869.
121. King AG, Horowitz D, Dillon SB et al. Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRObeta. Blood 2001;97:1534-1542.
122. Pelus LM, Bian H, King AG et al. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/ CXCL2 and GRObetaT/CXCL2delta4. Blood 2004;103:110-119.
123. Pruijt JF, Verzaal P, van OR et al. Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. Proc Natl Acad Sci USA 2002;99:6228-6233.
124. Kimura T, Boehmler AM, Seitz G et al. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD341 progenitor cells. Blood 2004;103:4478-4486.
125. Ryser MF, Ugarte F, Lehmann R et al. S1P(1) overexpression stimulates S1P-dependent chemotaxis of human CD341 hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent migration and in vivo homing. Mol Immunol 2008;46:166-171.
126. Seitz G, Boehmler AM, Kanz L et al. The role of sphingosine 1- phosphate receptors in the trafficking of hematopoietic progenitor cells. Ann N Y Acad Sci 2005;1044:84-89.
127. Allende ML, Tuymetova G, Lee BG et al. S1P1 receptor directs the release of immature B cells from bone marrow into blood. J Exp Med 2010;207:1113-1124.
128. Massberg S, Schaerli P, Knezevic-Maramica I et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 2007;131:994-1008.
129. Ratajczak MZ, Lee H, Wysoczynski M et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/ membrane attack complex. Leukemia 2010;24:976-985.
130. Golan K, Vagima Y, Ludin A et al. S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release. Blood 2012;119:2478-2488.
131. Juarez JG, Harun N, Thien M et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood 2012;119:707-716.
132. Ratajczak J, Kucia M, Mierzejewska K et al. A novel view of paroxysmal nocturnal hemoglobinuria pathogenesis: More motile PNH hematopoietic stem/progenitor cells displace normal HSPCs from their niches in bone marrow due to defective adhesion, enhanced migration and mobilization in response to erythrocyte-released sphingosine- 1 phosphate gradient. Leukemia 2012;26:1722-1725.
133. Ratajczak MZ, Borkowska S, Ratajczak J. An emerging link in stem cell mobilization between activation of the complement cascade and the chemotactic gradient of sphingosine-1-phosphate. Prostaglandins Other Lipid Mediat 2013;104-105:122-129.
134. Hoggatt J, Pelus LM. Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking. Leukemia 2010;24:1993-2002.
135. Hoggatt J, Singh P, Sampath J et al. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009;113:5444-5455.
136. Hoggatt J, Mohammad KS, Singh P et al. Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature 2013;494:365-369.
137. Katayama Y, Battista M, Kao WM et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006;124:407-421.
138. Spiegel A, Shivtiel S, Kalinkovich A et al. Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD341 cells through Wnt signaling. Nat Immunol 2007;8:1123-1131.
139. Gruber-Olipitz M, Stevenson R, Olipitz W et al. Transcriptional pattern analysis of adrenergic immunoregulation in mice. Twelve hours norepinephrine treatment alters the expression of a set of genes involved in monocyte activation and leukocyte trafficking. J Neuroimmunol 2004;155:136-142.
140. DiPersio JF, Stadtmauer AP, Nademanee AP et al. A phase III, multicenter, randomized, double blind, placebo-controlled, comparative trial of AMD3100 (Perixafor)1G-CSF vs. G-CSF1placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [abstract]. Blood 2007;110:137a.
141. DiPersio JF, Stadtmauer EA, Nademanee A et al. Plerixafor and GCSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-5726.
142. DiPersio JF, Micallef IN, Stiff PJ et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767-4773.
143. Pelus LM. Peripheral blood stem cell mobilization: New regimens, new cells, where do we stand. Curr Opin Hematol 2008;15:285-292.
144. Kymes SM, Pusic I, Lambert DL et al. Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care 2012;18:33-41.
145. Chen AI, Bains T, Murray S et al. Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplant 2012;47:1526-1529.
146. Costa LJ, Alexander ET, Hogan KR et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:64-69.
147. Micallef IN, Sinha S, Gastineau DA et al. Cost-effectiveness analysis of a risk-Adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2013;19:87-93.
148. Fruehauf S, Veldwijk MR, Seeger T et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: Results of a European phase II study. Cytotherapy 2009;11: 992-1001.
149. Hoggatt J, Pelus LM. Hematopoietic stem cell mobilization with agents other than G-CSF. Methods Mol Biol 2012;904:49-67.
150. Pelus LM, Fukuda S. Peripheral blood stem cell mobilization: The CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. Exp Hematol 2006;34:1010-1020.
151. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348:593-600.
152. Larochelle A, Krouse A, Metzger M et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006;107:3772-3778.